Casodex Disease Interactions

Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment. Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment. Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Clinical monitoring of hepatic function is recommended. Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.